120 related articles for article (PubMed ID: 37070826)
1. Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis.
Cheng C; Wang D; Yu M; Zhai Y; Pan C; Liang B; Zhang J; Wang C; Yin Y; Li L; Wu F; Shi Z; Fan X; Liu X; Wang Z; Zhao Z; Li G; Jiang T; Zhang W;
Neurosurgery; 2023 Oct; 93(4):802-812. PubMed ID: 37070826
[TBL] [Abstract][Full Text] [Related]
2. Histone H3.3 G34-mutant Diffuse Gliomas in Adults.
Wang L; Shao L; Li H; Yao K; Duan Z; Zhi C; Song S; Cheng Y; Wang F; Wang W; Piao Y; Gui Q; Lu D; Qi X; Teng L
Am J Surg Pathol; 2022 Feb; 46(2):249-257. PubMed ID: 34352809
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
5. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
6. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
Pekmezci M; Rice T; Molinaro AM; Walsh KM; Decker PA; Hansen H; Sicotte H; Kollmeyer TM; McCoy LS; Sarkar G; Perry A; Giannini C; Tihan T; Berger MS; Wiemels JL; Bracci PM; Eckel-Passow JE; Lachance DH; Clarke J; Taylor JW; Luks T; Wiencke JK; Jenkins RB; Wrensch MR
Acta Neuropathol; 2017 Jun; 133(6):1001-1016. PubMed ID: 28255664
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of H3 K27M-mutant gliomas in adults.
Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
9. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
10. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
11. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
12. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
13. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
14. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
[TBL] [Abstract][Full Text] [Related]
15. Letter: Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis.
Rahman S; Ahmed Khan R; Chowdhury M; Hasan M; Haque MR; Rahman MM
Neurosurgery; 2024 Apr; 94(4):e59-e60. PubMed ID: 38206039
[No Abstract] [Full Text] [Related]
16. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
Patel SH; Bansal AG; Young EB; Batchala PP; Patrie JT; Lopes MB; Jain R; Fadul CE; Schiff D
AJNR Am J Neuroradiol; 2019 Jul; 40(7):1149-1155. PubMed ID: 31248860
[TBL] [Abstract][Full Text] [Related]
17. Commentary: Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis.
Blobner J; Tonn JC
Neurosurgery; 2023 Oct; 93(4):e92. PubMed ID: 37186882
[No Abstract] [Full Text] [Related]
18. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
[TBL] [Abstract][Full Text] [Related]
20. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
